Semaglutide: A Breakthrough Treatment for Obesity and Diabetes—Are You Eligible?
A recent study shows that over half of U.S. adults can qualify for Ozempic. Around 137 million Americans are eligible for semaglutide, sold under the names of Rybelsus, Wegovy, and Ozempic.
This is a commonly prescribed drug and helps in managing type 2 diabetes and supporting weight loss for people who are overweight or obese.
If you’re curious about semaglutide and you want to know if it’s right for you, the best thing to do is to consult your doctor, but you can get some insights in this article.
The Widespread Eligibility
As semaglutide continues to gain popularity, the cost remains a major hurdle for many people. In the U.S., a supply for a month of Ozempic can set you back about $900, and Wegovy costs around $1,350. These costs are not covered by insurance, unfortunately, so for many people, it’s difficult to access it.
Dr. Ivy Shi and Dr. Dhruv S. Kazi decided to dive deeper into understanding how many people are eligible for semaglutide and what it means for federal health spending. They found the eligibility criteria for the clinical trial used in the Nutrition Examination Survey (NHANES) and the National Health. These studies are long-running, and they track the health and nutritional status of U.S. residents.
As their research shed light on the widespread need for those medications, it also underscored the challenge of being accessible for the people who qualify.
Their analysis showed that 8,504 out of 25,531 participants in the programs were eligible for semaglutide. Applying those results to the entire U.S. adult population, it’s estimated that nearly 137 million people could qualify for this life-changing medical prescription.
The average age is around 50, and the participants are half women.
Researchers highlighted the rates of obesity and the health issues coming along with it, like type 2 diabetes, and major factors driving up the number of people eligible for semaglutide.
They noted that the people eligible for Ozempic are more than the ones eligible for statins, a drug widely prescribed to lower cholesterol.
Eliud Sifonte, clinical assistant professor in endocrinology at NYU Grossman School of Medicine, explained that this unusual fact makes sense. “Not everyone with excess body fat has high cholesterol, so it’s expected that more people would be eligible for weight loss medications like semaglutide compared to those needing statins.”.
Dr. Shi thinks that there is more to discover about the benefits of semaglutide and who can use this treatment. “We’re seeing emerging data showing how effective semaglutide can be for conditions like chronic kidney disease and certain types of heart failure, which could increase its use in the future.”
The scientists who had this initiative hope that understanding the vast number of people who could benefit from these medications will help in pushing for more equitable access and ensure that people who can get benefits from using it can actually get to use it.
Do You Qualify?
If you’re wondering if you’re one person from the millions who qualify for semaglutide-based medication like Ozempic or Wegovy, let’s find out. Both of them require weekly injections, but if you’re looking for a daily option, Rybelsus is another semaglutide medication that comes in a once-daily tablet.
These medications are approved by the FDA for some specific conditions. Rybelsus and Ozempic are prescribed for type 2 diabetes, and Wegovy is for weight management. Both of them have been approved to lower the risk of cardiovascular death, stroke, or heart attack in adults with cardiovascular disease.
While Ozempic hasn’t been officially approved for managing obesity, the habit of getting a prescription off-label exists. It’s a legal and common practice, and they do it to help patients in need of losing weight. When they consider whether to prescribe Wegovy or Ozempic, doctors use criteria focusing on body mass index (BMI), measuring the weight in relation to height.
You can qualify:
- If your BMI is 30 or higher
- If you have a BMI between 27 and 29, with an obesity-related condition such as high cholesterol or high blood pressure.
Who is not eligible?
However, this is not the right choice for everyone. You need to be at least 12 years old to qualify for a prescription, 18 for Rybelsus, according to their manufacturer, and of course, you need to be off allergies to semaglutide or any other ingredient.
Novo Nordisk, the manufacturer of Rybelsus, advises avoiding using these medications if you have a family history of medullary thyroid carcinoma, which is a rare thyroid cancer. Moreover, avoid it if you have multiple endocrine neoplasia syndrome type 2, a genetic disorder affecting the endocrine system.
Ozempic is not recommended for people with diabetic retinopathy and those who have kidney or pancreatic problems.
If you consider semaglutide, it’s a good idea to talk to your doctor first. A healthcare professional will ultimately assess your health and determine if this is the right solution for you.
Impact on Public Health and Treatment
Semaglutides have become a staple in managing type 2 diabetes and obesity, and it has the potential to go far beyond these two conditions. Scientists are beginning to explore its effectiveness in treating heart disease, chronic kidney disease, and non-alcoholic fatty liver disease. Studies with promising results suggest that semaglutide could be a game-changer in managing these conditions. With more data becoming available, semaglutides might be the future in treating a variety of health challenges.
Ozempic’s role in disease management: semaglutide is shifting the approach to weight loss. Traditional methods such as diet and exercise are difficult for individuals who struggle with metabolic conditions and obesity. That’s why semaglutides are a viable alternative that helps people achieve significant weight loss, particularly when combined with lifestyle changes.
Patients who had struggled for years to lose weight found success with the help of semaglutide, providing a boost in appetite control and satiety.
Alternatives
Semaglutide is not the only medication for weight loss. There are other options, such as liraglutide (Saxenda) or orlistat (Alli), that also offer weight management solutions. However, semaglutide has shown higher success rates in clinical trials. Compared to these alternatives, semaglutide has the ability to improve blood sugar control and reduce the risk of heart disease. This might soon be an edge for patients dealing with multiple health concerns.
Conclusion
We have a groundbreaking treatment that offers hope for millions who struggle with type 2 diabetes and obesity. Its ability to help manage blood sugar levels is proven, as well as promoting weight loss and reducing the risk of heart disease.
With so many benefits, there is no surprise that so many are turning to this medication for support. Researches show that a large part of the population could benefit from semaglutide, but the challenge resides in accessibility, due to limited insurance coverage and high costs.
This is a valuable option for the ones who meet the criteria and need help managing their health. If you believe you might qualify, speak to your healthcare provider who can help you determine the best course of action.
With more data emerging about the potential benefits for other conditions such as heart disease or chronic kidney disease, the future seems promising for semaglutide’s role in public health transformation.
Ultimately, the key to achieving success with this treatment doesn’t only lie in access, but in a combination of healthy lifestyle choices for lasting change.
If you’re looking for more information, you can find on Amazon a guide called: The Use of Ozempic: The Complete Guide to Its Contribution to Diabetes Management and Weight Loss in Health
Read next: 5 Secrets From Melania Trump’s Book To Stay Calm and Confident
